Was ist die Webseite?

PDC Therapeutics

Startseite
Schweiz
Epalinges
PDC Therapeutics

PDC Therapeutics is a clinical stage biotech company, developing targeted Polymer Drug Conjugates for targeted chemotherapy.

29/04/2026

This year, Swiss Biotech Day brings a new layer of excitement.

PDC Therapeutics is ambitious as a Switzerland-based company that helps carry strong science into clinical and business development.

Our Co-Founder and COO Dr. Sena Nomak will join the biotech community in Basel at a time when PDC Therapeutics is no longer carrying only the promise of a platform. We are now scientifically backing a lead program, RS-0139, that has successfully completed Phase 1 and has helped show what Sagitta® can enable when strong science is matched with disciplined ex*****on.

Looking forward to the conversations in Basel, with clinical-stage progress and a clear path ahead for co-development.

08/03/2026

Women in science do not only contribute to progress. Their leadership expands what progress can look like for a better future. From discovery to development, from technology to co-development, women turn strong ideas into progress that can make a difference globally.

At PDC Therapeutics, we believe innovation grows stronger when scientific depth meets disciplined ex*****on. That is why women in science and entrepreneurship matter so deeply to us.

Cheers to the changemaker women building the future of biotech across labs and ecosystems, making innovation more connected and more ambitious.

11/02/2026

On the International Day of Women and Girls in Science, we recognise the women whose work turns ideas into therapies: in the lab, in development teams and across the life sciences ecosystem.

At PDC Therapeutics, we see how progress depends on scientific depth and disciplined ex*****on. We also see how excellence travels across generations when women inspire young girls who dream of making a difference in the future.

To the women and girls shaping the next generation of drug development, we are glad you are here and we are committed to building the kind of environment where you can lead.

w/ Rana Sanyal

29/12/2025

2026 begins with momentum.

Building technology to remove real bottlenecks in drug development takes courage and conviction. At PDC Therapeutics, we turn strong science into solutions designed to travel further, scale better and reach patients sooner.

With strong roots and clear confidence in what we do, we work alongside partners across borders. We know, and consistently demonstrate, that progress accelerates when ecosystems move together. No single player moves the needle alone; aligned efforts do.

The year ahead is about delivery: advancing programs, strengthening collaborations and discovering new ways to achieve what was once considered impossible.

We’re ready for what’s next. And we’re moving forward to our target, without compromise.

19/11/2025

Innovation begins with bold ideas and women continue to lead the way. 💪

On Women’s Entrepreneurship Day, we celebrate the women in biotech whose courage, creativity and vision shape the future of targeted therapies. Their resilience and leadership are transforming complex science into hope for patients worldwide. 🌍

Their leadership reminds us that diversity drives discovery and collaboration fuels progress.

23/10/2025

With a fall calendar so dynamic that even flight trackers can’t keep up, the spotlight has turned to one of the biggest questions in biotech: how do strategy and alliances shape the next breakthrough therapies?

At PDC Therapeutics, we arrive with a clear mission: to challenge the longstanding efficacy-toxicity trade-off in targeted therapies. Through scientific dedication and collaboration with our partners, we are building smarter pipelines to deliver safer solutions, working toward a future where effective therapies have no compromise.

Next stop: 🚀Vienna, for BIO-Europe 2025!

As one of Europe’s premier biotech gatherings, BIO-Europe offers the perfect backdrop to reconnect with our ecosystem, recalibrate our next steps and rediscover where we stand in the future of therapeutic innovation.

We’re excited to share the latest progress of our validated drug delivery platform, Sagitta®, and offer a preview of what’s ahead, including our upcoming Series B funding round.

Let’s meet in Vienna to explore how our immediate next milestones could shape both the future of biotech and a key inflection point in our company’s growth story.

25/09/2025

Today we celebrate the pharmacists who work hand in hand with scientists to advance targeted therapies. 💊

At PDC Therapeutics, their expertise in research and development ensures every step, from molecule to medicine, is uncompromised.

17/09/2025

For PDC Therapeutics, patient safety is the uncompromising foundation of science.

Our targeted therapies are developed to act precisely where they are needed, ensuring maximum effect with minimal risk. Because in cancer care, safety cannot be optional.

20/05/2025

Clinical trials are more than protocols; they are proof of potential. Every molecule is backed by rigorous trials and a shared commitment to making a difference.

Let’s take a moment to salute the researchers, participants and partners driving science forward on .

At PDC Therapeutics, we build bridges between discovery and care, licensing our clinically validated Sagitta® drug delivery technology to support the clinical success of high-potential, targeted therapies.

29/04/2025

We’re heading back to Basel for Swiss Biotech Day 2025: a cornerstone of Switzerland’s innovation-driven biotech landscape. As a proud part of the Swiss Biotech community, we look forward to exchanging insights, strengthening connections and showcasing how we’re advancing targeted therapies that make a difference.

Let’s connect and explore how precision innovation can unlock better outcomes in biotech. 🇨🇭

26/04/2025

In biotech, it takes more than a good idea to deliver results. It requires a solid intellectual property strategy to shield game-changing innovations, like ours. By leveraging the advanced capabilities of our Sagitta® drug delivery technology, we transform novel concepts into real-world solutions through strategic partnerships.

IP is the cornerstone that turns promising science into patient-ready therapies. Driving co-development projects, realizing the potential of our next-generation technology in tackling current challenges and addressing the needs of investors, partners and stakeholders to fuel further innovation is our superpower — but it isn’t easy. By securing IP at every step, we create the confidence and momentum needed to move high-potential therapies from bench to bedside. After all, protecting innovation is what transforms bold ideas into life-changing breakthroughs.

08/03/2025

Innovation thrives when diversity leads the way. On this International Women’s Day, we recognize the remarkable women shaping the future of healthcare. Their expertise and vision redefine possibilities, making a lasting impact on patients’ lives.

Adresse

Epalinges
1066

Webseite

https://pdcbio.com/

Benachrichtigungen

Lassen Sie sich von uns eine E-Mail senden und seien Sie der erste der Neuigkeiten und Aktionen von PDC Therapeutics erfährt. Ihre E-Mail-Adresse wird nicht für andere Zwecke verwendet und Sie können sich jederzeit abmelden.